Skip to main content

Publisher: Wiley-Blackwell

Volume 14, Number 9, 1 September 2012

Favourites:
ADD

Comparison between sitagliptin as add‐on therapy to insulin and insulin dose‐increase therapy in uncontrolled Korean type 2 diabetes: CSI study
pp. 795-802(8)
Authors: Hong, E. S.; Khang, A. R.; Yoon, J. W.; Kang, S. M.; Choi, S. H.; Park, K. S.; Jang, H. C.; Shin, H.; Walford, G. A.; Lim, S.

Favourites:
ADD

Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis
pp. 803-809(7)
Authors: Pantalone, K. M.; Kattan, M. W.; Yu, C.; Wells, B. J.; Arrigain, S.; Jain, A.; Atreja, A.; Zimmerman, R. S.

Favourites:
ADD

Utility of non‐high‐density lipoprotein cholesterol in assessing incident type 2 diabetes risk
pp. 821-825(5)
Authors: Ley, S. H.; Harris, S. B.; Connelly, P. W.; Mamakeesick, M.; Gittelsohn, J.; Wolever, T. M.; Hegele, R. A.; Zinman, B.; Hanley, A. J.

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes
pp. 859-864(6)
Authors: Heise, T.; Hermanski, L.; Nosek, L.; Feldman, A.; Rasmussen, S.; Haahr, H.

Favourites:
ADD
Favourites:
ADD

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more